Left ventricular assist devices (LVADs) were introduced as a bridge to cardiac transplantation for patients with end-stage heart failure.
This paper discusses reverse remodeling associated with left ventricular assist devices in patients with end-stage heart failure.
the last 2 decades, numerous advancements in medical therapies have improved patient outcomes in heart failure (HF). However, a significant number of patients still progress to end-stage HF, in which treatment options are largely limited to cardiac transplantation. As patient demands for transplant continue to exceed the supply of available organs, mechanical assist devices-specifically, the left ventricular assist device (LVAD)-were initially introduced as a bridge to cardiac transplantation.
Ambardekar et al. (Tue,) conducted a review in Heart failure. Left ventricular assist devices (LVAD) was evaluated. Left ventricular assist devices (LVADs) were introduced as a bridge to cardiac transplantation for patients with end-stage heart failure.